Synthetic biology is a rapidly evolving technology that first emerged in the 21st century. It combines various fields of science and technology, including biotechnology, automation, information technology, and manufacturing. Synthetic biology has been extensively applied in medicine, the environment, and agriculture.
Synthetic biology has created a variety of novel diagnostics and therapeutic approaches. For instance, synthetic biology enabled its synthesis from yeast instead of the Chinese sweet wormwood plant in the development of antimalarial treatment artemisinin. This technology has significantly helped stabilize the cost of treatment worldwide. Developing biosensors for rapid, accurate, and on-site detection of sugar levels and other biomolecules also helped with constant health monitoring.
The discovery of CRISPR/Cas, a novel gene editor, has enabled the precise editing of sequence-specific genes. This technique is used to develop various genetic disease models and determine therapies for human genetic diseases.
Synthetic biology has created a variety of novel diagnostics and therapeutic approaches. For instance, synthetic biology enabled its synthesis from yeast instead of the Chinese sweet wormwood plant in the development of antimalarial treatment artemisinin. This technology has significantly helped stabilize the cost of treatment worldwide. Developing biosensors for rapid, accurate, and on-site detection of sugar levels and other biomolecules also helped with constant health monitoring.
The discovery of CRISPR/Cas, a novel gene editor, has enabled the precise editing of sequence-specific genes. This technique is used to develop various genetic disease models and determine therapies for human genetic diseases.
The development of therapeutic antibodies via a conventional system requires immunization of rabbits or mice and, subsequently, isolating antibodies from sera. Another strategy involves harvesting antibodies from convalescent patients. These are time-consuming approaches. Synthetic biology can rapidly synthesize the genes related to the production of antibodies. This technique enables the development of synthetic human antibody libraries containing thousands of different antibodies, from which researchers can identify the optimal therapeutic molecules using advanced computational tools. This process assists in the rapid production of therapeutic antibodies for the treatment of a specific disease.
Another contribution of synthetic biology is the automation of antibody production, i.e., from the production of new antibodies to their characterization by assessing high-throughput affinity and functional testing. This approach has also reduced the developmental cost of therapeutic antibodies.
In 2016, synthetic biology led to the discovery of a novel immune cell engineering treatment, which enhanced the remission rate of terminally ill blood cancer patients by 50%. This technique was also found to be effective for patients with advanced breast cancer. A new type of tumor-attacking oncolytic virus has been developed, which can track and kill tumor cells in the brain.
KD-SmCARTM is a synthetic biology discovery platform established by KAEDI. There are no similar platforms reported at home and abroad. The technical level is domestically leading and world advanced. The KD-SmCARTM technology platform has successfully developed multiple Class I CARs New medicine pipeline.Depending on the company's advanced synthetic biology technology platform KD-SmCARTM, KAEDI has successfully developed many kinds of R&D pipelines for malignant tumor CAR-T, including next generation CAR-T, dual targeting 4th-generation CAR-T, triple-targeted 5th-generation CAR-T and allogeneic universal CAR-T, more than 10 of domestic and foreign patents have been declared.
KAEDI promotes CAR-T cell therapy and other immunotherapy through the advanced synthetic biology technology platform-KD-SmCARTM, thereby helping more patients.
KD-SmCARTM is a synthetic biology discovery platform established by KAEDI. There are no similar platforms reported at home and abroad. The technical level is domestically leading and world advanced. The KD-SmCARTM technology platform has successfully developed multiple Class I CARs New medicine pipeline.Depending on the company's advanced synthetic biology technology platform KD-SmCARTM, KAEDI has successfully developed many kinds of R&D pipelines for malignant tumor CAR-T, including next generation CAR-T, dual targeting 4th-generation CAR-T, triple-targeted 5th-generation CAR-T and allogeneic universal CAR-T, more than 10 of domestic and foreign patents have been declared.
KAEDI promotes CAR-T cell therapy and other immunotherapy through the advanced synthetic biology technology platform-KD-SmCARTM, thereby helping more patients.